Adial Pharmaceuticals, Inc.

1001 Research Park Blvd., Suite 100
Charlottesville, Virginia 22911


March 28, 2019



United States Securities

    and Exchange Commission
Division of Corporation Finance

100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Jeffrey Gabor


  Re: Adial Pharmaceuticals, Inc.
    Registration Statement on Form S-1, as amended
    File No: 333-230470

Dear Mr. Gabor:

Adial Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-230470), be accelerated by the U.S. Securities and Exchange Commission to Monday, April 1, 2019, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.

The Registrant hereby authorizes Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.


  Very truly yours,
  By:  /s/ William B. Stilley III



William B. Stilley III
Chief Executive Officer



Joseph Truluck, Chief Financial Officer, Adial Pharmaceuticals, Inc.

Leslie Marlow, Esq., Gracin & Marlow, LLP